ClinicalTrials.gg
CompletedNCT04705922Updated Jan 3, 2024

Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers

A Phase 1 interventional study of TT-00420 Capsule and TT-00420 Tablet in Healthy, sponsored by TransThera Sciences (Nanjing), Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-03.

Sponsored by TransThera Sciences (Nanjing), Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This study is an open-label, 3-way crossover randomized study in adult healthy volunteers to evaluate the relative bioavailability of TT-00420 tablet and capsule formulations and to evaluate food effect on the pharmacokinetics of TT-00420 tablet.

Read the detailed description

Subjects will be randomized to one of three treatment sequences. Each sequence will contain up to 8 subjects. In each treatment sequence, subjects undergo a baseline/screening period, three treatment periods, and a follow-up visit.

Subjects will be administered a single dose of TT-00420 on Day 1 of either TT-00420 tablet under fed condition, TT-00420 tablet under fasting condition, or capsule under fasting condition and crossed over after at least a 14-day washout period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

TransThera Sciences (Nanjing), Inc. is the lead sponsor of 19 studies on the registry; 7 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 18 and 64 years of age inclusive, at the time of signing the .
  2. (BMI) between 18 and 32 kg/m2, inclusive, and weighs at least 50 kg.
  3. Healthy as determined by the investigator based on medical history, clinical laboratory results (serum chemistry, hematology, urinalysis, and serology), vital sign measurements, 12-lead (ECG) results, and physical examination findings. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only, if per the investigator discretion, the investigator judges and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  4. Male subjects must not donate sperm starting at Screening, throughout the study period and for at least 90 days after final study drug administration.
  5. Male subjects with female sexual partner(s) of may be enrolled if the male:

    1. is documented to be surgically sterile (i.e., successfully vasectomized), or
    2. agrees to use 2 methods of highly effective and agree to refrain from sperm donation from the time of Screening through 90 days post-doseHighly effective includes male condom with spermicide PLUS an effective contraceptive for the female partner that includes: OCPs, long-acting implantable hormones, injectable hormones, a vaginal ring or IUD
  6. If female, is of non-, meeting the following requirements:

    1. pre-menopausal with documentation of surgical sterilization (i.e., hysterectomy, bilateral tubal ligation, bilateral oophorectomy, or bilateral salpingectomy at least 3 months prior to study entry), or
    2. defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and with follicle-stimulating hormone (FSH) level ≥ 40 mIU/mL at Screening
  7. Able to sign the informed consent and comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Any history of clinically serious disease.
  2. Any active or unstable medical condition as judged by the Investigator.
  3. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
  4. or allergy to any of the study drugs or drugs of similar chemical classes.
  5. Hypersensitivity or allergy for components of the prescribed meal
  6. Received any drug within 30 days or 5 half-lives(whichever is longer, if known) before the study.
  7. Subject who has undergone major surgery ≤ 2 months before study drug administration.
  8. Impaired cardiac function including clinically significant arrhythmias or clinically significant abnormality in clinical test, including but not limited to any of the following at Screening and Admission, repeat testing is allowed for verification, at the discretion of the Investigator:

    1. Heart rate \< 45 beats per minute (bpm) or > 90 bpm.
    2. Systolic blood pressure (SBP) \< 90 mmHg or > 140 mmHg; diastolic blood pressure (DBP) \< 50 mmHg or > 90 mmHg.
    3. Average of the 3 corrected using Fridericia's formula (QTcF) > 450 milliseconds.
    4. Troponin I at screening > (ULN).
    5. Second degree or higher Atrioventricular block on .
  9. Subject who has a known history of, or a positive test result for, surface antigen (HBsAg), immunoglobulin M (IgM) antibody to hepatitis B core antibody (anti-HBc) (IgM anti-HBc), virus antibody (anti-HCV), or (HIV) types 1 or 2, or syphilis at Screening.
  10. Subject with a history of severe visual diseases; or visual changes including flushing lights, blurry vision, color changes, or other visual changes.
  11. Subject who has used prescription or over-the-counter (OTC) medication (other than ≤ 2 g/day paracetamol [acetaminophen] or ≤ 800-mg/day ibuprofen), vitamins, or herbal remedies, within 2 weeks or 5 half-lives (if known) before study drug administration, whichever is longer.
  12. Subject who has had a loss of more than 100 mL blood (e.g., a blood donation) within 2 months before study drug administration, or has received any blood, plasma, or transfusions within 3 months before Admission, or plans to donate blood during the study or within 3 months after the study.
  13. Subject who has a history of alcohol abuse (defined as an alcohol intake more than 21 units for males and 14 units for females per week) or a history of drug abuse within the 6 months before study drug administration, or a history of substance abuse deemed significant by the Investigator.
  14. Subject who smokes cigarettes or uses other nicotine-containing products (e.g., snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers), and has done so in the 3 months prior to Screening.
  15. Subject who has a positive test for alcohol or drugs of abuse (opiates, methadone, buprenorphine, methamphetamine, cocaine, cannabinoids, amphetamines, or cotinine) at Screening or Admission.
  16. Subject is unable to complete this study for other reasons or the Investigator believes that he or she should be excluded.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequence 1 [TT-00420 tablet, fed; TT-00420 tablet, fasted; TT-00420 capsule, fasted]

    Participants will receive a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions. There will be at least a 14-day wash-out period between each dose.

    Drug: TT-00420 Capsule · Drug: TT-00420 Tablet

  • Experimental
    Sequence 2 [TT-00420 tablet, fasted; TT-00420 capsule, fed; TT-00420 tablet, fed]

    Participants will receive a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions. There will be at least a 14-day wash-out period between each dose.

    Drug: TT-00420 Capsule · Drug: TT-00420 Tablet

  • Experimental
    Sequence 3 [TT-00420 capsule, fasted; TT-00420 tablet, fed; TT-00420 tablet, fasted]

    Participants will receive a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions. There will be at least a 14-day wash-out period between each dose.

    Drug: TT-00420 Capsule · Drug: TT-00420 Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC0-∞) of TT-00420

    Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.

    Time frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)

  2. Area under the curve (AUC0-t) of TT-00420

    Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.

    Time frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)

  3. Maximum observed concentration (Cmax) of TT-00420

    Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.

    Time frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: From admission up to 10 days following discharge

  2. Incidence of abnormal physical examinations

    Time frame: At baseline and from admission to discharge, up to 12 days per period (each period is 14 days)

  3. Incidence of abnormal clinical laboratory tests

    Time frame: At baseline and from admission to discharge, up to 12 days per period (each period is 14 days)

  4. Incidence of abnormal vital signs

    Time frame: At baseline and from admission to discharge, up to 12 days per period (each period is 14 days)

  5. Incidence of abnormal weight

    Time frame: At baseline and from admission to discharge, up to 12 days per period (each period is 14 days)

  6. Incidence of abnormal 12-lead electrocardiogram

    Time frame: At baseline and from admission to discharge, up to 12 days per period (each period is 14 days)

  7. Half life (t1/2) of TT-00420

    Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.

    Time frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)

  8. Time of maximum concentration (tmax) of TT-00420

    Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.

    Time frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)

  9. Volume of distribution (Vd/F) of TT-00420

    Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.

    Time frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)

  10. Clearance (CL/F) of TT-00420

    Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.

    Time frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)

07

Study locations

1 site
  • Pharmaron CPC
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Mar 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2021
First posted
Jan 12, 2021
StartActual
Dec 29, 2020
Primary completionActual
Mar 7, 2021
CompletionActual
Jul 23, 2021
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04705922
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Jan 12, 2021
Start date
Dec 29, 2020
Primary completion
Mar 7, 2021
Completion
Jul 23, 2021
Last update
Jan 3, 2024

Study contacts

Mohamed Al-Ibrahim
principal investigator · Pharmaron CPC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinengotinib

Start the discussion